Suggestions
Gerry Smith
Biotech reporter at Bloomberg News
Gerry Smith is a renowned media reporter currently associated with Bloomberg News, bringing a wealth of experience from esteemed organizations like the Huffington Post and Chicago Tribune.
Gerry Smith pursued a Master of Science in Journalism from the prestigious Medill School of Journalism and obtained a Bachelor of Arts in English from Wake Forest University, showcasing a strong educational foundation in journalism and language studies.
Throughout his career, Gerry has held various key roles in notable organizations, including Biotech Reporter, Media Reporter, and Technology Reporter at Bloomberg News, as well as reporter positions at The Huffington Post, Chicago Tribune, Cox Newspapers, and Agence France Presse.
With a diverse background covering intricate subjects like biotech, media, and technology, Gerry Smith's insightful reporting has garnered attention and established him as a respected figure in the journalism industry.
Whether investigating the latest advancements in biotechnology or delving into the dynamic landscape of media and technology, Gerry's work reflects his dedication to delivering informative and engaging stories to his audience.
Gerry Smith's dedication to the field shines through his past experiences as a reporter and correspondent, demonstrating a deep understanding of global issues and a commitment to presenting accurate and compelling news to the public.
Gerry's expertise, honed through years of reporting on various beats, coupled with his strong educational background and professional affiliations, positions him as a prominent figure in media journalism, driving insightful conversations and shaping the narrative on crucial topics.
His insights and reports have brought him accolades, making him a go-to source for reliable and timely information, establishing him as a trusted name in the fast-paced world of media reporting.
Highlights
A new nonaddictive painkiller from Vertex Pharmaceuticals is being hailed as a scientific breakthrough. It's poised to become the first new class of pain medication in more than two decades.
But that may not be enough to loosen the grip opioids have on American medicine. Despite their dismal reputation, opioids have two powerful things going for them: They’re cheap, and they work. Companies making safer alternatives face an uphill battle and hope new laws will level the playing field.
My latest for Bloomberg Businessweek:
Parents of kids with a rare muscle disease are wrestling with whether to get a $3.2 million drug that may not work. Any slowing of the disease’s progression is valuable, they say. But there’s the risk of side effects, and another consideration: This could be their only shot at getting gene therapy.
“We just have to remain hopeful.”
